Site Specific Conjugation Methods: Patents Behind Homogeneous ADC Manufacturing
24.0% concentration at the top. The five leading assignees hold 967 of 4,036 records in scope — a real concentration, but not a lock on the field. Filings rose from 219 in 2017 to a peak of 435 in 2021, then eased to 297 by 2024, a -32% move over that three-year span. 2025 and 2026 figures are still incomplete because publication typically lags filing by around 18 months, so the apparent tail should not be read as a slowdown yet.
- 1NOVARTIS AG8.0%
- 2AMBRX INC4.4%
- 3REGENERON PHARMACEUTICALS INC4.0%
- 4SEAGEN INC4.0%
- 5SILVERBACK THERAPEUTICS INC3.5%
See the full site specific conjugation methods analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about site specific conjugation patents
What counts as a site specific conjugation method in this patent landscape?
The dataset covers patents that combine a specified conjugation route — engineered cysteine, enzymatic conjugation such as transglutaminase tagging, or unnatural amino acid incorporation — with claims addressing drug-antibody ratio control, conjugation homogeneity, residual free drug or process robustness. This excludes generic ADC linker or payload patents that do not address site-specificity directly. The search string used to build this dataset requires both a conjugation-route term and a process-quality term to appear together, which keeps the scope focused on manufacturing consistency rather than general ADC chemistry.
Who are the leading patent holders in site specific conjugation?
The dataset ranks 100 assignees by patent family count, with the leading assignee holding 323 records and the top five together holding 967 records, or 24.0% of the 4,036 records in scope. That leaves the majority of filings spread across a long tail of smaller and single-filing entrants, so a single company does not control the field even though the top of the ranking is concentrated. Full assignee names and their exact record counts are available in the ranking table on this page rather than repeated here.
Is patent filing activity in site specific conjugation still growing?
Filing volume peaked at 435 records in 2021 and had declined to 297 by 2024, a -32% change over that three-year span. However, patent publication typically lags actual filing by around 18 months, so the lower counts shown for 2025 and 2026 in the dataset are provisional and will rise as more applications publish. The honest read is that the field passed its filing peak by 2021 and settled into a lower but still active plateau through 2024, not that it is in ongoing decline.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Site Specific Conjugation Methods covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.